Navigation Links
Bio-Rad Helix EIA ENA Screen Bulk Kit

ProductsBio-Rad Helix EIA ENA Screen Bulk Kit
Company Bio-Rad Laboratories
Item Bio-Rad Helix EIA ENA Screen Bulk Kit
Features 
  • 576 Tests Per Kit
    • Description The ANA and ENA assays can be used to screen out patients negative for antinuclear antibodies, which are associated with various systemic rheumatic diseases such as Systemic lupus erythematosus (Lupus), Sjgren's syndrome, mixed connective tissue disease, progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. They can also be used in conjunction with our individual antibody assays to identify specific autoantibodies.
    Info Bio-Rad Laboratories
    Customer Service: 1-800-2-BIORAD
    Web site: http://www.bio-rad.com

    Related medicine products :

    1. Bio-Rad ANA Screen
    2. Bio-Rad Helix EIA ANA Screen Kit
    3. Bio-Rad Helix EIA ANA Screen Bulk Kit
    4. Bio-Rad Helix EIA ENA + Screen Kit
    5. Bio-Rad Helix EIA ENA + Screen Bulk Kit
    6. Bio-Rad Helix EIA ENA Screen Kit
    7. Bio-Rad Helix EIA Lupus Screening Kit
    8. Bio-Rad Platelia Aspergillus EIA
    9. Automatic Tangent Screen
    10. 1-Meter Roll-Up Tangent Screen
    11. Welch Allyn Suresight™ Vision Screener (English)
    Other Medicine News:Health News:University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix 2Health News:University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix 3Health News:Cleveland Clinic Press Releases Journal-Writing Book 'Write for Life: Healing Body, Mind, and Spirit Through Journal Writing' by Sheppard B. Kominars, Ph.D. 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12Health News:Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2
    Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 1STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 2STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 3Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 1Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 2Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 3Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 4Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 5Tough yet stiff deer antler is materials scientists dream 10910 1Tough yet stiff deer antler is materials scientists dream 10910 2